Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kaname Miyamoto is active.

Publication


Featured researches published by Kaname Miyamoto.


Gastroenterology | 1990

Involvement of tumor necrosis factor-α in the pathogenesis of activated macrophage-mediated hepatitis in mice

Junichi Nagakawa; Ieharu Hishinuma; Kazuo Hirota; Kaname Miyamoto; Takashi Yamanaka; Kazuo Tsukidate; Kouichi Katayama; Isao Yamatsu

The possible involvement of tumor necrosis factor-alpha in the pathogenesis of an experimentally induced hepatitis was investigated. Balb/c mice were primed with Propionibacterium acnes to induce the infiltration of mononuclear cells into the liver. Immunohistochemical study showed that most of the accumulated mononuclear cells at 7 days were Mac-2 positive, suggesting that they were activated macrophages. An injection of lipopolysaccharide resulted in massive hepatic necrosis and high mortality in the mice within 24 hours. Plasma tumor necrosis factor-alpha activity initially rose sharply and then declined over 3 hours. The increase in plasma aminotransferase activity correlated well with the elevation of plasma tumor necrosis factor-alpha activity. Pretreatment with dexamethasone or 16,16-dimethyl-prostaglandin E2 attenuated not only the elevation of plasma tumor necrosis factor-alpha activity but also the increase in plasma aminotransferase activity and improved the survival rate. Passive immunization against tumor necrosis factor-alpha showed protective effects. These findings suggest that tumor necrosis factor-alpha released from activated macrophages may play a crucial role in the pathogenesis of this murine hepatitis.


Inflammation Research | 1992

Suppressive effects of E3330, a novel quinone derivative, on tumor necrosis factor-α generation from monocytes and macrophages

Kaname Miyamoto; Junichi Nagakawa; Ieharu Hishinuma; Kazuo Hirota; M. Yasuda; Takashi Yamanaka; Kouichi Katayama; Isao Yamatsu

E3330 {(2E)-3-[5-(2,3-dimethoxy-6-methyl-1,4-benzoquinoyl)]-2-nonly-2-propenoic acid}, a novel synthesized hepatoprotective compound, has suppressive effects on tumor necrosis factor-α (TNF-α) generation from monocytes/macrophagesin vitro. E3330 (1–100 μM) reduced lipopolysaccharide (LPS, 10 mg/ml or 1μg/ml)-induced TNF-α generation from rat resident andPropionibacterium acnes (P. acnes)-elicited peritoneal macrophages, rat and human monocytes, rat Kupffer cells, and splenic mononuclear cells in a concentration-dependent manner. E3330 also (1–100 μM) suppressed TNF-α generation stimulated with egg-albumin immune complex in ratP. acnes-elicited peritoneal macrophages. Northern blot analysis showed that LPS-induced expression of TNF-α messenger RNA (mRNA) in human blood monocytes was suppressed by E3330. These findings indicate that E3330 has a suppressive effect on TNF-α generation from monocytes/macrophages, regardless of origin or species, and this effect is based in part on the suppression of TNF-α mRNA expression.


European Journal of Pharmacology | 1992

Protective effects of E3330, a novel quinone derivative, on galactosamine/tumor necrosis factor-α-induced hepatitis in mice

Junichi Nagakawa; Ieharu Hishinuma; Kazuo Hirota; Kaname Miyamoto; Takashi Yamanaka; Isao Yamatsu; Kouichi Katayama

Oral pretreatment with E3330, a novel quinone derivative, attenuated liver injury induced with tumor necrosis factor-alpha in galactosamine-sensitized mice. Tumor necrosis factor-alpha is known to induce inflammatory mediators such as leukotrienes and prostanoids. An in vitro study showed that E3330 inhibited the generation of leukotriene B4 and thromboxane B2, but enhanced prostaglandin E2 generation from rat peritoneal exudate cells stimulated with the Ca(2+)-ionophore, A23187. These findings suggest that the protective effect of E3330 on galactosamine/tumor necrosis factor-alpha hepatitis is due at least in part to its inhibition of the generation of leukotrienes. The inhibition of thromboxane B2 generation or the enhancement of prostaglandin E2 generation by E3330 may also contribute to its hepatoprotective effect.


Immunopharmacology and Immunotoxicology | 1991

Interleukin-Lα Enhances Hepatotoxicity of Tumor Necrosis Factor-α in Galactosamine-Sensitized Mice

Junichi Nagakawa; Ieharu Hishinuma; Kazuo Hirota; Kaname Miyamoto; M. Yasuda; Takashi Yamanaka; Kouichi Katayama

AbstractThe possible involvement of interleukin-lα (IL-lα) in the pathogenesis of murine hepatitis model induced with galactosamine and lipopolysaccharide (LPS) was investigated. the injection of 10 ng/mouse of LPS in combination with 10 mg/mouse of galactosamine into mice induced hepatic damage at 24 hours. Treatment with anti-mouse IL-1α antiserum 30 min before galactosamine/LPS injection showed a tendency to reduce the liver injury, while pretreatment with anti-mouse tumor necrosis factor-α (TNF) antiserum significantly protected mice from liver injury. the use of recombinant murine TNF, instead of LPS, in combination with galactosamine could elicit hepatic damage, whereas recombinant murine IL-lα could not substitute for LPS. However, recombinant murine IL-lα enhanced the hepatotoxic effect of recombinant murine TNF in galactosamine-sensitized mice. These results suggest that TNF plays a major role in the pathogenesis of galactosamine/LPS hepatitis in mice and that IL-lα acts synergistically with TNF ...


Hepatology | 1990

Involvement of tumor necrosis factor-α in development of hepatic injury in galactosamine-sensitized mice

Ieharu Hishinuma; Junichi Nagakawa; Kazuo Hirota; Kaname Miyamoto; Kazuo Tsukidate; Takashi Yamanaka; Kouichi Katayama; Isao Yamatsu


Archive | 1990

Quinone derivatives and pharmacological use

Shinya Abe; Yasushi Okamoto; Katsuya Tagami; Shigeki Hibi; Junichi Nagakawa; Kazuo Hirota; Ieharu Hishinuma; Kaname Miyamoto; Takashi Yamanaka; Hiromitsu Yokohama; Tsutomu Yoshimura; Tohru Horie; Yasunori Akita; Koichi Katayama; Isao Yamatsu


Antimicrobial Agents and Chemotherapy | 1998

Suppression of Murine Endotoxin Response by E5531, a Novel Synthetic Lipid A Antagonist

Seiichi Kobayashi; Tsutomu Kawata; Akifumi Kimura; Kaname Miyamoto; Koichi Katayama; Isao Yamatsu; Daniel P. Rossignol; William J. Christ; Yoshito Kishi


Folia Pharmacologica Japonica | 1988

[Effects of E-3123, a new protease inhibitor, on several protease activities and on experimental acute pancreatitis].

Kaname Miyamoto; Ieharu Hishinuma; Junichi Nagakawa; Naoko Nagaoka; Takashi Yamanaka; Tsuneo Wakabayashi


Journal of Medicinal Chemistry | 1996

Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase

Shigeki Hibi; Yasushi Okamoto; Katsuya Tagami; Hirotoshi Numata; Naoki Kobayashi; Masanobu Shinoda; Tetsuya Kawahara; Koukichi Harada; Kaname Miyamoto; Isao Yamatsu


Archive | 1990

Guanidinobenzoic ester derivative

Shigeru Souda; Naoyuki Shimomura; Norihiro Ueda; Shuhei Miyazawa; Takashi Yamanaka; Kaname Miyamoto; Ieharu Hishinuma; Junichi Nagakawa; Naoko Nagaoka; Hidetoshi Kawashima; Tsutomu Kawata; Junsaku Nagaoka; Tsuneo Wakabayashi

Collaboration


Dive into the Kaname Miyamoto's collaboration.

Researchain Logo
Decentralizing Knowledge